1
|
Johnson S, Karpova Y, Guo D, Ghatak A, Markov DA, Tulin AV. PARG suppresses tumorigenesis and downregulates genes controlling angiogenesis, inflammatory response, and immune cell recruitment. BMC Cancer 2022; 22:557. [PMID: 35585513 PMCID: PMC9118775 DOI: 10.1186/s12885-022-09651-9] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2021] [Accepted: 05/09/2022] [Indexed: 12/20/2022] Open
Abstract
Chemokines are highly expressed in tumor microenvironment and play a critical role in all aspects of tumorigenesis, including the recruitment of tumor-promoting immune cells, activation of cancer-associated fibroblasts, angiogenesis, metastasis, and growth. Poly (ADP-ribose) polymerase (PARP) is a multi-target transcription regulator with high levels of poly(ADP-ribose) (pADPr) being reported in a variety of cancers. Furthermore, poly (ADP-ribose) glycohydrolase (PARG), an enzyme that degrades pADPr, has been reported to be downregulated in tumor tissues with abnormally high levels of pADPr. In conjunction to this, we have recently reported that the reduction of pADPr, by either pharmacological inhibition of PARP or PARG's overexpression, disrupts renal carcinoma cell malignancy in vitro. Here, we use 3 T3 mouse embryonic fibroblasts, a universal model for malignant transformation, to follow the effect of PARG upregulation on cells' tumorigenicity in vivo. We found that the overexpression of PARG in mouse allografts produces significantly smaller tumors with a delay in tumor onset. As downregulation of PARG has also been implicated in promoting the activation of pro-inflammatory genes, we also followed the gene expression profile of PARG-overexpressing 3 T3 cells using RNA-seq approach and observed that chemokine transcripts are significantly reduced in those cells. Our data suggest that the upregulation of PARG may be potentially useful for the tumor growth inhibition in cancer treatment and as anti-inflammatory intervention.
Collapse
Affiliation(s)
- Sarah Johnson
- Department of Biomedical Sciences, School of Medicine and Health Sciences, University of North Dakota, Grand Forks, ND 58202 USA
| | - Yaroslava Karpova
- Department of Biomedical Sciences, School of Medicine and Health Sciences, University of North Dakota, Grand Forks, ND 58202 USA
- Koltzov Institute of Developmental Biology of Russian Academy of Sciences, Moscow, 119334 Russia
| | - Danping Guo
- Department of Biomedical Sciences, School of Medicine and Health Sciences, University of North Dakota, Grand Forks, ND 58202 USA
| | - Atreyi Ghatak
- Department of Biomedical Sciences, School of Medicine and Health Sciences, University of North Dakota, Grand Forks, ND 58202 USA
| | - Dmitriy A. Markov
- Department of Cell Biology and Neuroscience, School of Osteopathic Medicine, Rowan University, Stratford, NJ 08084 USA
| | - Alexei V. Tulin
- Department of Biomedical Sciences, School of Medicine and Health Sciences, University of North Dakota, Grand Forks, ND 58202 USA
| |
Collapse
|
2
|
Guerrero-Aspizua S, González-Masa A, Conti CJ, García M, Chacón-Solano E, Larcher F, del Río M. Humanization of Tumor Stroma by Tissue Engineering as a Tool to Improve Squamous Cell Carcinoma Xenograft. Int J Mol Sci 2020; 21:ijms21061951. [PMID: 32178458 PMCID: PMC7139348 DOI: 10.3390/ijms21061951] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2020] [Revised: 02/26/2020] [Accepted: 03/09/2020] [Indexed: 12/26/2022] Open
Abstract
The role of stroma is fundamental in the development and behavior of epithelial tumors. In this regard, limited growth of squamous cell carcinomas (SCC) or cell-lines derived from them has been achieved in immunodeficient mice. Moreover, lack of faithful recapitulation of the original human neoplasia complexity is often observed in xenografted tumors. Here, we used tissue engineering techniques to recreate a humanized tumor stroma for SCCs grafted in host mice, by combining CAF (cancer associated fibroblasts)-like cells with a biocompatible scaffold. The stroma was either co-injected with epithelial cell lines derived from aggressive SCC or implanted 15 days before the injection of the tumoral cells, to allow its vascularization and maturation. None of the mice injected with the cell lines without stroma were able to develop a SCC. In contrast, tumors were able to grow when SCC cells were injected into previously established humanized stroma. Histologically, all of the regenerated tumors were moderately differentiated SCC with a well-developed stroma, resembling that found in the original human neoplasm. Persistence of human stromal cells was also confirmed by immunohistochemistry. In summary, we provide a proof of concept that humanized tumor stroma, generated by tissue engineering, can facilitate the development of epithelial tumors in immunodeficient mice.
Collapse
Affiliation(s)
- Sara Guerrero-Aspizua
- Department of Bioengineering, Universidad Carlos III de Madrid, 28911 Leganés, Spain; (A.G.-M.); (C.J.C.); (M.G.); (E.C.-S.); (F.L.); (M.d.R.)
- Hospital Fundación Jiménez Díaz e Instituto de Investigación FJD, 28040 Madrid, Spain
- Epithelial Biomedicine Division. CIEMAT, 28040 Madrid, Spain
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), U714, 28911 Madrid, Spain
- Correspondence: ; Tel.: +34-91-624-8206
| | - Andrea González-Masa
- Department of Bioengineering, Universidad Carlos III de Madrid, 28911 Leganés, Spain; (A.G.-M.); (C.J.C.); (M.G.); (E.C.-S.); (F.L.); (M.d.R.)
| | - Claudio J. Conti
- Department of Bioengineering, Universidad Carlos III de Madrid, 28911 Leganés, Spain; (A.G.-M.); (C.J.C.); (M.G.); (E.C.-S.); (F.L.); (M.d.R.)
- Hospital Fundación Jiménez Díaz e Instituto de Investigación FJD, 28040 Madrid, Spain
| | - Marta García
- Department of Bioengineering, Universidad Carlos III de Madrid, 28911 Leganés, Spain; (A.G.-M.); (C.J.C.); (M.G.); (E.C.-S.); (F.L.); (M.d.R.)
- Hospital Fundación Jiménez Díaz e Instituto de Investigación FJD, 28040 Madrid, Spain
- Epithelial Biomedicine Division. CIEMAT, 28040 Madrid, Spain
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), U714, 28911 Madrid, Spain
| | - Esteban Chacón-Solano
- Department of Bioengineering, Universidad Carlos III de Madrid, 28911 Leganés, Spain; (A.G.-M.); (C.J.C.); (M.G.); (E.C.-S.); (F.L.); (M.d.R.)
- Hospital Fundación Jiménez Díaz e Instituto de Investigación FJD, 28040 Madrid, Spain
- Epithelial Biomedicine Division. CIEMAT, 28040 Madrid, Spain
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), U714, 28911 Madrid, Spain
| | - Fernando Larcher
- Department of Bioengineering, Universidad Carlos III de Madrid, 28911 Leganés, Spain; (A.G.-M.); (C.J.C.); (M.G.); (E.C.-S.); (F.L.); (M.d.R.)
- Hospital Fundación Jiménez Díaz e Instituto de Investigación FJD, 28040 Madrid, Spain
- Epithelial Biomedicine Division. CIEMAT, 28040 Madrid, Spain
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), U714, 28911 Madrid, Spain
| | - Marcela del Río
- Department of Bioengineering, Universidad Carlos III de Madrid, 28911 Leganés, Spain; (A.G.-M.); (C.J.C.); (M.G.); (E.C.-S.); (F.L.); (M.d.R.)
- Hospital Fundación Jiménez Díaz e Instituto de Investigación FJD, 28040 Madrid, Spain
- Epithelial Biomedicine Division. CIEMAT, 28040 Madrid, Spain
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), U714, 28911 Madrid, Spain
| |
Collapse
|
3
|
Adhikari P, Nagesh PKB, Alharthi F, Chauhan SC, Jaggi M, Yallapu MM, Pradhan P. Optical detection of the structural properties of tumor tissue generated by xenografting of drug-sensitive and drug-resistant cancer cells using partial wave spectroscopy (PWS). BIOMEDICAL OPTICS EXPRESS 2019; 10:6422-6431. [PMID: 31853408 PMCID: PMC6913405 DOI: 10.1364/boe.10.006422] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/25/2019] [Accepted: 11/06/2019] [Indexed: 06/10/2023]
Abstract
A mesoscopic physics-based optical imaging technique, partial wave spectroscopy (PWS), has been used for the detection of cancer by probing nanoscale structural alterations in cells/tissue. The development of drug-resistant cancer cells/tissues during chemotherapy is a major challenge in cancer treatment. In this paper, using a mouse model and PWS, the structural properties of tumor tissue grown in 3D structures by xenografting drug-resistant and drug-sensitive human prostate cancer cells having 2D structures, are studied. The results show that the 3D xenografted tissues maintain a similar hierarchy of the degree of structural disorder properties as that of the 2D original drug-sensitive and drug-resistant cells.
Collapse
Affiliation(s)
- Prakash Adhikari
- Department of Physics and Astronomy, Mississippi State University, Mississippi State, MS 39762, USA
| | - Prashanth K B Nagesh
- Department of Immunology and Microbiology, School of Medicine, University of Texas-Rio Grande Valley, McAllen, TX 78504, USA
| | - Fatemah Alharthi
- Department of Physics and Astronomy, Mississippi State University, Mississippi State, MS 39762, USA
| | - Subhash C Chauhan
- Department of Immunology and Microbiology, School of Medicine, University of Texas-Rio Grande Valley, McAllen, TX 78504, USA
| | - Meena Jaggi
- Department of Immunology and Microbiology, School of Medicine, University of Texas-Rio Grande Valley, McAllen, TX 78504, USA
| | - Murali M Yallapu
- Department of Immunology and Microbiology, School of Medicine, University of Texas-Rio Grande Valley, McAllen, TX 78504, USA
| | - Prabhakar Pradhan
- Department of Physics and Astronomy, Mississippi State University, Mississippi State, MS 39762, USA
| |
Collapse
|
4
|
Sampera A, Sánchez-Martín FJ, Arpí O, Visa L, Iglesias M, Menéndez S, Gaye É, Dalmases A, Clavé S, Gelabert-Baldrich M, Poulsen TT, Kragh M, Bellosillo B, Albanell J, Rovira A, Montagut C. HER-Family Ligands Promote Acquired Resistance to Trastuzumab in Gastric Cancer. Mol Cancer Ther 2019; 18:2135-2145. [DOI: 10.1158/1535-7163.mct-19-0455] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2019] [Revised: 07/28/2019] [Accepted: 08/27/2019] [Indexed: 11/16/2022]
|
5
|
Kamposioras K, Tsimplouli C, Verbeke C, Anthoney A, Daoukopoulou A, Papandreou CN, Sakellaridis N, Vassilopoulos G, Potamianos SP, Liakouli V, Migneco G, Del Galdo F, Dimas K. Silencing of caveolin-1 in fibroblasts as opposed to epithelial tumor cells results in increased tumor growth rate and chemoresistance in a human pancreatic cancer model. Int J Oncol 2018; 54:537-549. [PMID: 30483772 PMCID: PMC6317659 DOI: 10.3892/ijo.2018.4640] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2017] [Accepted: 04/03/2018] [Indexed: 01/27/2023] Open
Abstract
Caveolin-1 (Cav-1) expression has been shown to be associated with tumor growth and resistance to chemotherapy in pancreatic cancer. The primary aim of this study was to explore the significance of Cav-1 expression in pancreatic cancer cells as compared to fibroblasts in relation to cancer cell proliferation and chemoresistance, both in vitro and in vivo, in an immunodeficient mouse model. We also aimed to evaluate the immunohistochemical expression of Cav-1 in the epithelial and stromal component of pancreatic cancer tissue specimens. The immunohistochemical staining of poorly differentiated tissue sections revealed a strong and weak Cav-1 expression in the epithelial tumor cells and stromal fibroblasts, respectively. Conversely, the well-differentiated areas were characterized by a weak epithelial Cav-1 expression. Cav-1 downregulation in cancer cells resulted in an increased proliferation in vitro; however, it had no effect on chemoresistance and growth gain in vivo. By contrast, the decreased expression of Cav-1 in fibroblasts resulted in a growth advantage and the chemo-resistance of cancer cells when they were co-injected into immunodeficient mice to develop mixed fibroblast/cancer cell xenografts. On the whole, the findings of this study suggest that the downregulation of Cav-1 in fibroblasts is associated with an increased tumor proliferation rate in vivo and chemoresistance. Further studies are warranted to explore whether the targeting of Cav-1 in the stroma may represent a novel therapeutic approach in pancreatic cancer.
Collapse
Affiliation(s)
| | - Chrysiida Tsimplouli
- Department of Pharmacology, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41500 Larissa, Greece
| | | | - Alan Anthoney
- Department of Medical Oncology, The Leeds Teaching Hospitals NHS Trust, LS9 7TF Leeds, UK
| | - Argyro Daoukopoulou
- Department of Pharmacology, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41500 Larissa, Greece
| | - Christos N Papandreou
- Department of Medical Oncology, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41110 Larissa, Greece
| | - Nikolaos Sakellaridis
- Department of Pharmacology, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41500 Larissa, Greece
| | - George Vassilopoulos
- Department of Hematology, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41110 Larissa, Greece
| | - Spyros P Potamianos
- Department of Gastroenterology, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41110 Larissa, Greece
| | - Vasiliki Liakouli
- Scleroderma Programme, Leeds Institute of Rheumatic and Musculoskeletal Medicine, LMBRU, University of Leeds, LS9 7TF Leeds, UK
| | - Gemma Migneco
- Division of Oncology, Leeds Institute of Molecular Medicine, St. James's University Hospital Leeds, LS9 7TF Leeds, UK
| | - Francesco Del Galdo
- Scleroderma Programme, Leeds Institute of Rheumatic and Musculoskeletal Medicine, LMBRU, University of Leeds, LS9 7TF Leeds, UK
| | - Konstantinos Dimas
- Department of Pharmacology, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41500 Larissa, Greece
| |
Collapse
|
6
|
Shi P, Liao M, Chuang BC, Griffin R, Shi J, Hyer M, Fallon JK, Smith PC, Li C, Xia CQ. Efflux transporter breast cancer resistance protein dominantly expresses on the membrane of red blood cells, hinders partitioning of its substrates into the cells, and alters drug-drug interaction profiles. Xenobiotica 2018; 48:1173-1183. [PMID: 29098941 DOI: 10.1080/00498254.2017.1397812] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2017] [Revised: 10/23/2017] [Accepted: 10/24/2017] [Indexed: 01/13/2023]
Abstract
1. Red blood cell (RBC) partitioning is important in determining pharmacokinetic and pharmacodynamic properties of a compound; however, active transport across RBC membranes is not well understood, particularly without transporter-related cell membrane proteomics data. 2. In this study, we quantified breast cancer resistance protein (BCRP/Bcrp) and MDR1/P-glycoprotein (P-gp) protein expression in RBCs from humans, monkeys, dogs, rats and mice using nanoLC/MS/MS, and evaluated their effect on RBC partitioning and plasma exposure of their substrates. BCRP-specific substrate Cpd-1 and MDR1-specific substrate Cpd-2 were characterized using Caco-2 Transwell® system and then administered to Bcrp or P-gp knockout mice. 3. The quantification revealed BCRP/Bcrp but not MDR1/P-gp to be highly expressed on RBC membranes. The knockout mouse study indicated BCRP/Bcrp pumps the substrate out of RBCs, lowering its partitioning and thus preventing binding to intracellular targets. This result was supported by a Cpd-1 and Bcrp inhibitor ML753286 drug-drug interaction (DDI) study in mice. Because of enhanced partitioning of Cpd-1 into RBCs after BCRP/Bcrp inhibition, Cpd-1 plasma concentration changed much less extent with genetic or chemical knockout of Bcrp albeit marked blood concentration increase, suggesting less DDI effect. 4. This finding is fundamentally meaningful to RBC partitioning, pharmacokinetics and DDI studies of BCRP-specific substrates.
Collapse
MESH Headings
- ATP Binding Cassette Transporter, Subfamily B/genetics
- ATP Binding Cassette Transporter, Subfamily B/metabolism
- ATP Binding Cassette Transporter, Subfamily G, Member 2/antagonists & inhibitors
- ATP Binding Cassette Transporter, Subfamily G, Member 2/genetics
- ATP Binding Cassette Transporter, Subfamily G, Member 2/metabolism
- Animals
- Caco-2 Cells
- Chromatography, Liquid
- Drug Interactions
- Erythrocyte Membrane/drug effects
- Erythrocyte Membrane/metabolism
- Female
- Humans
- Macaca fascicularis
- Mice, Inbred BALB C
- Mice, Knockout
- Neoplasm Proteins/antagonists & inhibitors
- Neoplasm Proteins/metabolism
- Rats
- Tandem Mass Spectrometry
- ATP-Binding Cassette Sub-Family B Member 4
Collapse
Affiliation(s)
- Pu Shi
- a Drug Metabolism and Pharmacokinetics, Takeda Pharmaceuticals International Co , 35 Landsdowne Street, Cambridge, MA , USA
| | - Mingxiang Liao
- a Drug Metabolism and Pharmacokinetics, Takeda Pharmaceuticals International Co , 35 Landsdowne Street, Cambridge, MA , USA
| | - Bei-Ching Chuang
- a Drug Metabolism and Pharmacokinetics, Takeda Pharmaceuticals International Co , 35 Landsdowne Street, Cambridge, MA , USA
| | - Robert Griffin
- a Drug Metabolism and Pharmacokinetics, Takeda Pharmaceuticals International Co , 35 Landsdowne Street, Cambridge, MA , USA
| | - Judy Shi
- b Cancer Pharmacology, Takeda Pharmaceuticals International Co , 40 Landsdowne Street, Cambridge, MA , USA , and
| | - Marc Hyer
- b Cancer Pharmacology, Takeda Pharmaceuticals International Co , 40 Landsdowne Street, Cambridge, MA , USA , and
| | - John K Fallon
- c Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill , Chapel Hill , NC , USA
| | - Philip C Smith
- c Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill , Chapel Hill , NC , USA
| | - Chao Li
- a Drug Metabolism and Pharmacokinetics, Takeda Pharmaceuticals International Co , 35 Landsdowne Street, Cambridge, MA , USA
| | - Cindy Q Xia
- a Drug Metabolism and Pharmacokinetics, Takeda Pharmaceuticals International Co , 35 Landsdowne Street, Cambridge, MA , USA
| |
Collapse
|